Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma

References

• Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood 2008;111:504–516.
   PubMed Web of Science ®Google Scholar
• Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010;51:25–30.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Loft A, Hansen M, et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 2006;91:482–489.
   PubMed Web of Science ®Google Scholar
• Weihrauch MR, Re D, Bischoff S, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002;81: 20–25.
   PubMed Web of Science ®Google Scholar
• Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005;104:1066–1074.
   PubMed Web of Science ®Google Scholar
• Rigacci L, Vitolo U, Nassi L, et al. Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 2007;86:897–903.
   PubMed Web of Science ®Google Scholar
• Munker R, Glass J, Griffeth LK, et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol 2004;15:1699–1704.
   PubMed Web of Science ®Google Scholar
• Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004;90:620–625.
   PubMed Web of Science ®Google Scholar
• Partridge S, Timothy A, O’Doherty MJ, et al. 2-Fluorine-18- fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol 2000;11:1273–1279.
   PubMed Web of Science ®Google Scholar
• Salaun PY, Gastinne T, Bodet-Milin C, et al. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging 2009;36: 1813–1821.
   PubMed Web of Science ®Google Scholar
• Synopsis of the observational study of the interim PET in patients with Hodgkin lymphoma. Available from: www.plrg.pl/index.php/badania/pozostale
   Google Scholar
• Boellaard R, O’Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181–200.
   PubMed Web of Science ®Google Scholar
• Retif P, Jegouic C, Slosman DO. Quality assessment of fluorodeoxyglucose positron emission tomography imaging in clinical setting: definition of standard quality control parameters for patients treated for lymphoma. Nucl Med Commun 2011;32:794–801.
   PubMed Web of Science ®Google Scholar
• Picardi M, Soricelli A, Grimaldi F, et al. Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen. Ann Oncol 2011;22:671–680.
   PubMed Web of Science ®Google Scholar
• Pelosi E, Penna D, Deandreis D, et al. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management. Q J Nucl Med Mol Imaging 2008;52:9–16.
   PubMed Web of Science ®Google Scholar
• Tardivon AA, Munck JN, Shapeero LG, et al. Can clinical data help to screen patients with lymphoma for MR imaging of bone marrow? Ann Oncol 1995;6:795–800.
   PubMed Web of Science ®Google Scholar
• Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340–3346.
   PubMed Web of Science ®Google Scholar
• Schaefer NG, Strobel K, Taverna C, et al. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 2007;34:60–67.
   PubMed Web of Science ®Google Scholar
• El-Galaly TC, d’Amore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 2012;30:4508–4514.
   PubMed Web of Science ®Google Scholar
• Nakamoto Y, Cohade C, Tatsumi M, et al. CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology 2005;237:627–634.
   PubMed Web of Science ®Google Scholar
• Purz S, Mauz-Korholz C, Korholz D, et al.[18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma. J Clin Oncol 2011;29:3523–3528.
   PubMed Web of Science ®Google Scholar
• Elstrom RL, Tsai DE, Vergilio JA, et al. Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow. Clin Lymphoma 2004;5:62–64.
   PubMedGoogle Scholar
• Moulin-Romsee G, Hindie E, Cuenca X, et al. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging 2010;37:1095–1105.
   PubMed Web of Science ®Google Scholar
• Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012;307: 2418–2429.
   PubMed Web of Science ®Google Scholar
• Diederich S, Link TM, Zuhlsdorf H, et al. Pulmonary manifestations of Hodgkin's disease: radiographic and CT findings. Eur Radiol 2001;11:2295–2305.
   PubMed Web of Science ®Google Scholar
• Pelosi E, Pregno P, Penna D, et al. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol Med 2008;113:578–590.
   PubMed Web of Science ®Google Scholar
• Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease:coregistered FDG PET and CT at staging and restaging—do we need contrast-enhanced CT? Radiology 2004;232: 823–829.
   PubMed Web of Science ®Google Scholar
• Connors JM, Gascoyne RD, Hoskins P, et al. Hodgkin lymphoma patients with stage II B or stage II bulky disease have advanced disease and should not be included in limited stage trials. Blood 2010;116(Suppl. 1): Abstract 417.
   Google Scholar
• Barrington SF, Mikhaeel NG. When should FDG-PET be used in the modern management of lymphoma? Br J Haematol 2014; 164:315–328.
   PubMed Web of Science ®Google Scholar